Abstract
Background The COVID-19 pandemic triggered an unprecedented rise in mortality that translated into life expectancy losses around the world, with only a few exceptions. In 2021, life expectancy trends globally diverged more due to the unequal impact of the pandemic across countries, variation in the age-patterns of mortality, and differences in vaccination. We estimate life expectancy changes in 29 countries since 2020, attribute them to mortality changes by age group, and compare them to historic life expectancy shocks.
Data Total death counts by age and sex came from the Short-term Mortality Fluctuations and Human Mortality databases. Registered COVID-19 deaths and vaccination counts by age and sex were sourced from the COVerAGE-DB database. Midyear population counts were extracted from the UN World Population Prospects database.
Methods Life expectancy for females, males, and the total population were calculated for 29 countries for 2020 and 2021. Additionally, we calculated life expectancy deficits for 2020 and 2021 based on pre-pandemic Lee-Carter forecasts of short-term life expectancy trends. Using demographic decomposition techniques, age- and COVID-19 specific contributions to changes and deficits in life expectancy were calculated. Deficits in life expectancy in 2021 across countries were compared to country vaccination rates. 95% uncertainty intervals were derived from Poisson replications of death counts.
Findings Out of 29 countries, 14 countries lost life expectancy in both 2020 and 2021, 12 recovered losses in 2020 but not all of them back to 2019 levels, 2 exceeded pre-pandemic life expectancy, and 1 dropped below 2019 levels only in 2021. All 29 countries had lower life expectancy in 2021 than expected had pre-pandemic trends continued. The female life expectancy advantage increased for most countries, consistent with hypotheses that females are more resilient to mortality crises than men. Life expectancy losses were moderately correlated with measures of vaccination uptake. One notable change from 2020 was that mortality at younger ages contributed more to life expectancy losses in 2021. Registered COVID-19 deaths accounted for most losses of life expectancy.
Interpretation In 2021 we saw divergence in the impact of the pandemic on population health. While some countries saw bounce-backs from stark life expectancy losses, others experienced sustained and substantial life expectancy deficits. While COVID-19 has been the most severe global mortality shock since the Second World War, this observed heterogeneity in 2021 indicates that pathways to long-term recovery of life expectancy trends remain unclear.
Funding British Academy’s Newton International Fellowship grant NIFBA19/190679 (J.M.A., R.K.); ROCK-WOOL Foundation’s Excess Deaths grant (J.M.A., I.K.); Leverhulme Trust Large Centre Grant (J.M.A., L.Z., R.K., J.B.D.); European Research Council grant ERC-2021-CoG-101002587 (MOR-TAL) (J.B.D.); University of Oxford John Fell Fund (J.M.A., L.Z., R.K., J.B.D.); Estonian Research Council grant PSG 669 (H.J.).
Evidence before this study The COVID-19 pandemic disrupted mortality trends around the world. Most high-income countries experienced life expectancy declines in 2020, and emerging evidence from low-to-middle income shows substantial losses in life expectancy with large regional variation. These analyses emphasise the impact of COVID-19 deaths and also highlight the effect of excess mortality at older ages as the main contributor to life expectancy losses, although in some countries working-age mortality also contributed substantially to life expectancy reductions. Only a few countries including Denmark, Norway, Finland, Australia, South Korea, Iceland and New Zealand did not experience life expectancy losses.
Added value of this study We estimate life expectancy for 29 countries in 2020/21 and assess bounce-backs versus mounting losses. We determine which age groups contributed most to life expectancy changes in 2021, and analyze how age patterns of excess mortality changed between 2020 and 2021. By projecting pre-pandemic mortality trends into 2020/21 we calculate the life expectancy deficit induced by the pandemic. We compare age-specific life expectancy deficits in 2021 against vaccination uptake by age group and further decompose the deficit into contributions from COVID-19 versus non-COVID mortality. To contextualize the magnitude of life expectancy loss, we compare the 2020/21 COVID-19 pandemic with historic mortality shocks over the 20th century. We report results for females, males and the total population.
Implications of all the available evidence Life expectancy is an important summary measure of population health. Over the past decade, improvements in life expectancy have slowed in several countries. The COVID-19 pandemic has compounded these trends and disrupted life expectancy improvements across the globe. The pandemic increased life expectancy inequalities between countries, as life expectancy losses were higher among countries with lower pre-pandemic life expectancy. COVID-19 may be a short-term mortality shock, but it is unclear whether countries will bounce back to increasing life expectancy trends in the short- or medium-term. New variants continue the spread of SARS-CoV-2 globally. Variation in preventive measures and vaccine uptake has led to disparate mortality burdens across countries. The long-term mortality impacts of social and economic stressors due to the pandemic are not known, neither are the mortality implications of regular re-infection or Long-COVID. Going forward, it is crucial to understand how and why death rates vary across and within countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors of this study were funded by - British Academy's Newton International Fellowship grant NIFBA19/190679 (J.M.A., R.K.) - ROCKWOOL Foundation's Excess Deaths grant (J.M.A., I.K.) - Leverhulme Trust Large Centre Grant (J.M.A., L.Z., R.K., J.B.D.) - European Research Council grant ERC-2021-CoG-101002587 (MORTAL) (J.B.D.) - University of Oxford John Fell Fund (J.M.A., L.Z., R.K., J.B.D.) - Estonian Research Council grant PSG 669 (H.J.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In this study publicly available demographic data has been analyzed. Death counts by age and sex: - Short term mortality fluctuations database (https://www.mortality.org/Public/STMF/Outputs/stmf.csv) - Human mortality database (https://www.mortality.org) - Office for National Statistics England & Wales (https://www.ons.gov.uk/file?uri=/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathsregisteredinenglandandwalesseriesdrreferencetables/2019/finalreftables2019.xlsx) - Centers for Disease Control and Prevention United States (Underlying Cause of Death 1999-2019 on CDC WONDER Online Database. Accessed at http://wonder.cdc.gov/ucd-icd10.html on Feb 9, 2021) - COVerAGE-DB (https://osf.io/mpwjq/) Population estimates by age and sex: - for years 2000 to 2019: World Population Prospects 2019 single year-age population estimates 1950-2019 (https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/CSV_FILES/WPP2019_PopulationBySingleAgeSex_1950-2019.csv) - for year 2020: World Population Prospects 2019 single year-age population projections 2020-2100 (https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/CSV_FILES/WPP2019_PopulationBySingleAgeSex_2020-2100.csv) Vaccination rates by age: - COVerAGE-DB (https://osf.io/mpwjq/) External life-table data for validation: - United Nations World Population Prospects (https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/CSV_FILES/WPP2019_Life_Table_Medium.csv) - Human mortality database (https://www.mortality.org)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The analyses are fully reproducible with source code and data archived with Zenodo (\href{https://zenodo.org/record/6224984}{DOI: 10.5281/zenodo.6224984}). Additionally we archived CSV files of the table and figure data (\href{https://zenodo.org/record/6224376}{DOI: 10.5281/zenodo.6224376}), and the harmonized life table data informing all analyses in this paper (\href{https://zenodo.org/record/6241025}{DOI: 10.5281/zenodo.6241025}).
https://zenodo.org/record/6224984
